During the past 3 years, the average Free Cash Flow per Share Growth Rate was 21.50% per year.
During the past 5 years, the average Free Cash Flow per Share Growth Rate was 1.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.
During the past 6 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of Lyra Therapeutics was 21.50% per year. The lowest was -28.30% per year. And the median was 13.60% per year.
Competitive Comparison of Lyra Therapeutics's 3-Year FCF Growth Rate
For the Biotechnology subindustry, Lyra Therapeutics's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lyra Therapeutics's 3-Year FCF Growth Rate Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lyra Therapeutics's 3-Year FCF Growth Rate distribution charts can be found below:
* The bar in red indicates where Lyra Therapeutics's 3-Year FCF Growth Rate falls into.
This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.
Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.
Lyra Therapeutics 3-Year FCF Growth Rate Related Terms
Thank you for viewing the detailed overview of Lyra Therapeutics's 3-Year FCF Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.
Lyra Therapeutics (Lyra Therapeutics) Business Description
Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. The company's technology platform, XTreo, is designed to precisely and consistently deliver medicines directly to the affected tissue for sustained periods with a single administration. Its initial product candidates, LYR-210 and LYR-220, are bioresorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver up to six months of continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
LYRA has been successfully added to your